Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,602,888
  • Shares Outstanding, K 2,443,528
  • Annual Sales, $ 17,099 M
  • Annual Income, $ 5,906 M
  • 60-Month Beta 0.59
  • Price/Sales 7.20
  • Price/Cash Flow 18.99
  • Price/Book 16.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.63
  • Number of Estimates 2
  • High Estimate 0.63
  • Low Estimate 0.62
  • Prior Year 0.73
  • Growth Rate Est. (year over year) -13.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.60 +7.45%
on 02/28/19
52.83 -1.15%
on 03/20/19
+2.56 (+5.16%)
since 02/21/19
3-Month
43.60 +19.78%
on 12/26/18
52.83 -1.15%
on 03/20/19
+7.74 (+17.41%)
since 12/21/18
52-Week
41.23 +26.66%
on 10/11/18
52.83 -1.15%
on 03/20/19
+1.97 (+3.93%)
since 03/21/18

Most Recent Stories

More News
Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsvaerd, Denmark, 21 March 2019 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following resolutions were adopted:

NVO : 52.24 (-0.74%)
Emisphere Development Update

Novo Nordisk announced today it has submitted two New Drug Applications ("NDA") to the US Food and Drug Administration ("FDA") for oral semaglutide, a once-daily oral formulation of the long-acting GLP-1...

EMIS : 6.8800 (-0.86%)
NVO : 52.24 (-0.74%)
Novo Nordisk files for US FDA approval of oral semaglutide for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes

Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide, the first once-daily glucagon-like peptide-1 (GLP-1) receptor...

NVO : 52.24 (-0.74%)
Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic(R)

Bagsvaerd, Denmark, 20 March 2019 - Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide, a once-daily glucagon-like...

NVO : 52.24 (-0.74%)
Diabetes Drug Intelligence Center 2019: Global Database with Coverage Through 2012-2023 - Insulin Holds the Highest Market Share, and Sanofi, Novo Nordisk, and Eli Lilly Dominate - ResearchAndMarkets.com

The "Diabetes Drug Intelligence Center (2012-2023)" report has been added to ResearchAndMarkets.com's offering.

NVO : 52.24 (-0.74%)
Novo Nordisk settles US patent litigation case on Victoza(R) (liraglutide) with Teva

Bagsvaerd, Denmark, 18 March 2019 - Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza(R)...

NVO : 52.24 (-0.74%)
Anaqua to Host 13th Annual User Conference with Keynotes from Arm, EPO, IPWatchdog, Novo Nordisk, and Panasonic

Many of the world's top IP practitioners will come together for four days in March for a major industry event hosted by Anaqua, the leading provider of innovation and intellectual property...

NVO : 52.24 (-0.74%)
Anaqua to Host 13th Annual User Conference with Keynotes from Arm, EPO, IPWatchdog, Novo Nordisk, and Panasonic

Many of the world's top IP practitioners will come together for four days in March for a major industry event hosted by Anaqua, the leading provider of innovation and intellectual property...

NVO : 52.24 (-0.74%)
Lilly to Bring Half-Priced Version of Popular Humalog Insulin

Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

NVO : 52.24 (-0.74%)
LLY : 128.58 (+0.33%)
PFE : 42.42 (+0.59%)
SNY : 45.35 (-0.13%)
Novo Nordisk Pharma Ltd. partners with Health2Sync in Japan, bringing digital diabetes management to healthcare providers and patients

Health2Sync and Novo Nordisk Pharma Ltd. are partnering in Japan to support digital diabetes management and facilitate communication between diabetics and healthcare providers. Last December, the two companies...

NVO : 52.24 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 53.35
1st Resistance Point 52.99
Last Price 52.23
1st Support Level 52.11
2nd Support Level 51.59

See More

52-Week High 52.83
Last Price 52.23
Fibonacci 61.8% 48.40
Fibonacci 50% 47.03
Fibonacci 38.2% 45.66
52-Week Low 41.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar